论文部分内容阅读
目的探讨肺癌组织中多效蛋白(PTN)的表达及其临床意义。方法肺癌组织标本92例(肺癌组);其中,鳞癌46例(鳞癌组),腺癌31例(腺癌组),小细胞癌15例(小细胞癌组);良性病变肺组织标本15例(对照组)。采用组织芯片结合免疫组织化学法检测PTN的表达。结果 PTN蛋白主要表达于细胞的胞浆和胞膜。肺癌组PTN表达高于对照组(P<0.01)。小细胞癌组PTN表达高于鳞癌组和腺癌组(P<0.05)。PTN在肺癌患者中的表达量与肿瘤的TNM分期(P<0.05)、病理类型(P<0.05)及肿瘤分化程度(P<0.05)密切相关。结论 PTN在肺癌,尤其是小细胞肺癌组织中的表达异常增高,有可能成为新的肺癌诊断及预后肿瘤标志物。
Objective To investigate the expression of pleiotropic protein (PTN) in lung cancer and its clinical significance. Methods Forty-two patients with lung cancer (lung cancer group), including 46 squamous cell carcinomas (squamous cell carcinoma), 31 adenocarcinoma (adenocarcinoma), 15 small cell carcinomas (small cell carcinoma) 15 cases (control group). Tissue microarray combined with immunohistochemistry was used to detect the expression of PTN. Results PTN protein was mainly expressed in the cytoplasm and plasma membrane. The expression of PTN in lung cancer group was higher than that in control group (P <0.01). The expression of PTN in small cell carcinoma was higher than that in squamous cell carcinoma and adenocarcinoma (P <0.05). The expression of PTN in lung cancer patients was closely related to TNM staging (P <0.05), pathological type (P <0.05) and tumor differentiation (P <0.05). Conclusions The expression of PTN is abnormally elevated in lung cancer, especially in small cell lung cancer and may be a new tumor marker for diagnosis and prognosis of lung cancer.